Trial Profile
An Observational, Pilot Study Evaluating the Efficacy and Safety of Pertuzumab for the Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients in Real Life Setting
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2018
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Antineoplastics; Docetaxel; Paclitaxel; Trastuzumab
- Indications Breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PerTe
- 12 Jun 2018 New trial record
- 05 Jun 2018 Results (n=65) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.